Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) chief scientific officer, Professor Lindy Durrant, talked with Proactive's Stephen Gunnion about the company's groundbreaking results from the SCOPE trial. The trial focuses on SCIB1 in combination with double checkpoint inhibitors ipilimumab and nivolumab for advanced melanoma.
Professor Durrant highlighted that cohort one demonstrated an 84% disease control rate, with 72% of tumours shrinking and 20% completely clearing. The most exciting outcome was an 80% progression-free survival rate at six months, signalling durable and significant tumour control. This data underscores the potential for longer-term benefits in advanced cancer therapy.
She emphasised the importance of progression-free survival as a predictor for overall survival and explained its role as the endpoint for upcoming phase two/three registration studies. The discussion also covered the next steps in the trial, updates on iSCIB1+, and the company's other programs, including Modi-1 and their antibody platform.
Quoting Professor Durrant: “Once we get control of the tumour, we seem to maintain control.”
